Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 11:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Reflux Acid Clear all
Enrolling by invitation No phase listed Observational

Transoral Incisionless Fundoplication Database Repository (TIF)

NCT04306380
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
no intervention, database study
Other
Lead sponsor
Indiana University
Other
Eligibility
13 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 15, 2026, 11:44 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Nasopharyngeal 24 Hour pH Monitoring in Health Adult Volunteers

NCT00584675
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dx-pH Measurement Probe
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy for Insomnia (CBTI) in GERD Patients With Insomnia

NCT03904472
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Web-based CBTI
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 3 Interventional Results available

Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma

NCT03015610
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux
Interventions
commercially available lansoprazole, matched placebo
Drug
Lead sponsor
Jason Lang, M.D., M.P.H.
Other
Eligibility
6 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

NCT00132496
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole sodium
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 16 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Longmont, Colorado • Fort Lauderdale, Florida • New Port Richey, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Sep 15, 2026, 11:44 PM EDT
Not yet recruiting Phase 2 Interventional

Oral Fosamprenavir for GERD

NCT06704100
View directory record Official record
Conditions
Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease
Interventions
Fosamprenavir Calcium 700 MG Oral Tablet, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
50 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 15, 2026, 11:44 PM EDT
Completed No phase listed Observational

Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease

NCT02629081
View directory record Official record
Conditions
GERD
Interventions
Controls & Cases
Other
Lead sponsor
Loren Laine
Other
Eligibility
21 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease

NCT00215787
View directory record Official record
Conditions
Nasal Polyps, Gastroesophageal Reflux
Interventions
lansoprazole
Drug
Lead sponsor
Head and Neck Surgery Associates
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 3 Interventional

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171483
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Timeline
2004 – 2005
U.S. locations
7
States / cities
Boynton Beach, Florida • Miami, Florida • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2008 · Synced Sep 15, 2026, 11:44 PM EDT
Recruiting Not applicable Interventional

Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

NCT06783751
View directory record Official record
Conditions
Obesity, Bariatric Surgery, Sleeve Gastrectomy, Gastroesophageal Reflux Disease
Interventions
Modified Vertical Sleeve Gastrectomy (mVSG), Conventional Vertical Sleeve Gastrectomy (cVSG)
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Orange, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 15, 2026, 11:44 PM EDT
Enrolling by invitation Not applicable Interventional

Targeting Hypervigilance and Autonomic Arousal: the Psycho-physiologic Model of Gastroesophageal Reflux Disease (GERD)

NCT04960566
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Cognitive Behavioral Therapy, Sham-SOC Lifestyle Coaching
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 3 Interventional Results available

Phase 3/Safety & Efficacy of Esomeprazole in Infants

NCT00468559
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Month to 11 Months
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 4 Interventional Results available

Lansoprazole to Treat Children With Asthma

NCT00442013
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole, Matching placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 17 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 15, 2026, 11:44 PM EDT
Withdrawn Not applicable Interventional

HRIM vs Mucosal Impedance in GERD Participants

NCT02812407
View directory record Official record
Conditions
Gastro-esophageal Reflux Disease (GERD)
Interventions
Mucosal Impedance
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 15, 2026, 11:44 PM EDT
Completed No phase listed Observational

Endoscopic Full-Thickness Plication for the Treatment of GERD: Long-Term Multicenter Results

NCT00587392
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
NDO Full-thickness Plicator
Device
Lead sponsor
NDO Surgical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2008 · Synced Sep 15, 2026, 11:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

NCT04614974
View directory record Official record
Conditions
Laryngomalacia, Gastro Esophageal Reflux
Interventions
Famotidine, Speech Language Therapy
Drug · Other
Lead sponsor
Reema Padia
Other
Eligibility
0 Months to 6 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Omeprazole Decrease Intestinal Calcium Absorption?

NCT00582972
View directory record Official record
Conditions
Osteoporosis, Achlorhydria, GERD, Hip Fracture
Interventions
Omeprazole
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea

NCT00307944
View directory record Official record
Conditions
Acid Reflux Disease, Obstructive Sleep Apnea
Interventions
Pantoprazole
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease

NCT05343364
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 15, 2026, 11:44 PM EDT
Withdrawn Not applicable Interventional

Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing

NCT03270722
View directory record Official record
Conditions
Scleroderma, Dysphagia, GERD - Gastro-Esophageal Reflux Disease
Interventions
FLIP topography, Upper Endoscopy
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Not applicable Interventional Results available

VenaSeal Sapheon Closure System Pivotal Study (VeClose)

NCT01807585
View directory record Official record
Conditions
Great Saphenous Vein (GSV) With Venous Reflux Disease
Interventions
VenaSeal SCS, ClosureFast Radiofrequency Ablation (RFA), Roll-in (VenaSeal SCS)
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
21 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • San Diego, California • Greenwood Village, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 3 Interventional

Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171418
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Timeline
2003 – 2005
U.S. locations
2
States / cities
Metairie, Louisiana • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 27, 2008 · Synced Sep 15, 2026, 11:44 PM EDT
Recruiting Not applicable Interventional

Compassionate Use of Domperidone for Refractory Gastroparesis

NCT04699591
View directory record Official record
Conditions
GERD, Gastroesophageal Reflux, Gastroparesis
Interventions
Domperidone
Drug
Lead sponsor
Jose Cocjin
Other
Eligibility
12 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2035
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 15, 2026, 11:44 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658528
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 15, 2026, 11:44 PM EDT